1985 Volume 76 Issue 1 Pages 1-9
Fourty-seven patients with advanced stage D adenocarcinoma of the prostate were treated with the combination of vincristine, ifosfamide and peplomycin (VIP therapy).
Of these patients, 34 were refractory to prior hormonal therapy and 22 (64.7%) achieved an objective response (9 partial, 13 stable) using National Prostatic Cancer Project criteria in United States. In the patients of objective response, the response lasted from two to forty-three months with a median duration of 6.3 months.
Disappearance or significant decrease in bone pain was observed in 19 of 26 patients (73.1%). The survival period of the responders was significantly longer than that of the nonresponders (p<0.005). Moreover, among 13 patints who had not previously received hormonal therapy, eleven achieved an objective response (5 partial, 6 stable) for a 84.7 per cent reponse rate. The toxicity of VIP therapy was mild to moderate. We consider that VIP therapy is one of the most useful regimen for the treatment of the advanced adenocarcinoma of the prostate.
